The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial
| Autor: | Masafumi Ono, Roberto Botelho, Chao Gao, Pascal Vranckx, Christian W. Hamm, Ply Chichareon, Volker Schächinger, Imre Ungi, Gincho Tonev, Kuniaki Takahashi, Eric Eeckhout, Stephan Windecker, Robert-Jan van Geuns, Hironori Hara, Rutao Wang, Hideyuki Kawashima, Scot Garg, Rodrigo Modolo, Patrick W. Serruys, Yoshinobu Onuma, Mariusz Tomaniak, Norihiro Kogame, Peter Jüni |
|---|---|
| Přispěvatelé: | ACS - Heart failure & arrhythmias, Graduate School, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] education Myocardial Infarction Hemorrhage 030204 cardiovascular system & hematology Coronary artery disease Percutaneous coronary intervention 03 medical and health sciences 0302 clinical medicine Heart Rate Internal medicine medicine Clinical endpoint Humans Myocardial infarction Mortality 610 Medicine & health Pre-procedure heart rate Proportional hazards model business.industry Hazard ratio medicine.disease Confidence interval Treatment Outcome 030104 developmental biology Conventional PCI Cardiology and Cardiovascular Medicine business Follow-Up Studies Predictor |
| Zdroj: | Atherosclerosis, 303, 1-7. Elsevier Ireland Ltd Atherosclerosis, 303, pp. 1-7 Atherosclerosis, 303, 1-7 |
| ISSN: | 0021-9150 |
| Popis: | Contains fulltext : 225405.pdf (Publisher’s version ) (Open Access) BACKGROUND AND AIMS: The prognostic impact of pre-procedure heart rate (PHR) following percutaneous coronary intervention (PCI) has not yet been fully investigated. This post-hoc analysis sought to assess the impact of PHR on medium-term outcomes among patients having PCI, who were enrolled in the "all-comers" GLOBAL LEADERS trial. METHODS AND RESULTS: The primary endpoint (composite of all-cause death or new Q-wave myocardial infarction [MI]) and key secondary safety endpoint (bleeding according to Bleeding Academic Research Consortium [BARC] type 3 or 5) were assessed at 2 years. PHR was available in 15,855 patients, and when evaluated as a continuous variable (5 bpm increase) and following adjustment using multivariate Cox regression, it significantly correlated with the primary endpoint (hazard ratio [HR] 1.06, 95% confidence interval [CI] 1.03-1.09, p 67 bpm was associated with increased all-cause mortality (HR 1.38, 95%CI 1.13-1.69, p = 0.002) and more frequent new Q-wave MI (HR 1.41, 95%CI 1.02-1.93, p = 0.037). No significant association was found between PHR and BARC 3 or 5 bleeding (HR 1.04, 95% CI 0.99-1.09, p = 0.099). There was no interaction with the primary (p-inter = 0.236) or secondary endpoint (p-inter = 0.154) when high and low PHR was analyzed according to different antiplatelet strategies. CONCLUSIONS: Elevated PHR was an independent predictor of all-cause mortality at 2 years following PCI in the "all-comer" GLOBAL LEADERS trial. The prognostic value of increased PHR on outcomes was not affected by the different antiplatelet strategies in this trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect